SCHEMBL1007262

SCHEMBL1007262

O=C(NCc1cccs1)c1csc(Cn2nc(C(F)(F)F)c3c2CCCC3)n1

nearest known ligand 0.47

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.44
MEN1 O00255 2/20 0.44
ALDH1A1 P00352 1/20 0.44
HPGD P15428 1/20 0.44
LMNA P02545 6/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
TSHR P16473 2/20 0.43
NPC1 O15118 1/20 0.43
RAB9A P51151 1/20 0.43
SLC40A1 Q9NP59 1/20 0.42
MAPT P10636 4/20 0.42
TP53 P04637 2/20 0.42
NPSR1 Q6W5P4 1/20 0.41
GAA P10253 1/20 0.41
POLB P06746 1/20 0.41
KCNJ2 P63252 1/20 0.41
CPT1A P50416 1/20 0.41
POLQ O75417 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1007573 0.86 SMN1; SMN2 (0.49) LMNASMN1; SMN2TSHRMAPTTP53
SCHEMBL1007919 0.85 LMNA (0.47) ALDH1A1LMNASMN1; SMN2TSHRMAPT
SCHEMBL1007969 0.82 SMN1; SMN2 (0.46) KMT2ALMNASMN1; SMN2TSHRMAPT
SCHEMBL8000406 0.82 MAPT (0.53) LMNATSHRMAPTTP53NPSR1
SCHEMBL1007831 0.81 LMNA (0.51) KMT2AMEN1ALDH1A1LMNASMN1; SMN2
SCHEMBL1007241 0.81 LMNA (0.47) KMT2AMEN1ALDH1A1LMNASMN1; SMN2
SCHEMBL1007931 0.81 SMN1; SMN2 (0.62) LMNASMN1; SMN2TSHRMAPTTP53
SCHEMBL1007215 0.80 LMNA (0.56) ALDH1A1LMNATSHRMAPTTP53
SCHEMBL1008069 0.80 PARP1 (0.42) KMT2AMEN1ALDH1A1HPGDLMNA
SCHEMBL1006942 0.79 LMNA (0.46) KMT2AMEN1ALDH1A1HPGDLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110118236-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-05-19 US disclosed
US-20110118236-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-05-19 US disclosed
EP-2269990-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2011-01-05 EP disclosed
EP-2269990-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2011-01-05 EP disclosed
WO-2009119088-A1 HETEROCYCLIC COMPOUND 武田薬品工業株式会社 (JP) 2009-10-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110118236-A1 HETEROCYCLIC COMPOUND GRIN1, GRM1, GRIK1 KMT2A 1139/4885MEN1 1454/4885ALDH1A1 614/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.